Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

  • 13 Accesses

  • 7 Citations

Summary

In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bianchi R, Nardelli B, Allegrucci M, Fioretti MC (1985) Efficacia terapeutica del PTT-119 valutata in vivo in modelli sperimentali. G Ital Chemioter 32:1–16

  2. 2.

    De Barbieri A, Dall'Asta L, Comini A, De Barbieri A, Dall'Asta L, Comini A, Springolo V, Mosconi P, Coppi G, Be-kesi G (1983) Synthesis, acute toxicity and chemotherapeutic anti-cancer activity of a new tripeptidic mustard. Farmacc 38:205–218

  3. 3.

    Fisher RI, DeVita VT, Hubbard SM (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of Pro-Mace and MOPP chemotherapy. Ann Intern Med 98:304–309

  4. 4.

    Martoni A, Mazzei T, Mini E, Martoni A, Mazzei T, Mini E, Cellerino R, Periti P, Fioretto L, Pannuti F (1986) Phase I trial of a novel alkylating agent, PTT-119. Cancer Chemother Pharmacol 18: Abstr 192

  5. 5.

    McKelvey EM, Gottlieb JA, Wilson HE (1976) Hydroxyldaunomycin (adriamycin) combination chemotherapy in non-Hodgkin's lymphomas. Cancer 38:1484–1493

  6. 6.

    Portlock CS, Rosenberg SA (1976) Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas. Cancer 37:1275–1282

  7. 7.

    Schein PS, DeVita VT Jr, Hubbard S (1976) Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 85: 17–22

  8. 8.

    Yagi MJ, Zanjani M, Holland JF, Bekesi JG (1984) Increased cancericidal activity of PTT-119, a new synthetic bis-(2-chloroethyl)-amino-l-phenylanine derivative with carrier amino acids: 2. In vivo bioassay. Cancer Chemother Pharmacol 12: 77–82

  9. 9.

    Yagi MJ, Chin SE, Scanlon KJ, Holland JF, Bekesi G (1985) PTT-119, p-F-m-BIS-(2-chloroethyl)-amino-l-Phe-Met-Ethoxy HCl. A new chemotherapeutic agent active against drug-resistant tumor cell lines. Biochem Pharmacol 34:2347–2354

Download references

Author information

Correspondence to P. Mazza.

Additional information

This work was supported by Fondi Ministero Publica Istruzione

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tura, S., Mazza, P., Gherlinzoni, F. et al. Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. Cancer Chemother. Pharmacol. 23, 123–125 (1989). https://doi.org/10.1007/BF00273532

Download citation

Keywords

  • Lymphoma
  • Cancer Research
  • Diarrhea
  • Alopecia
  • Evaluable Patient